This article is more than 5 years old. Information may no longer be current.

Bausch + Lomb launches Lotemax SM

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch + Lomb has begun distributing Lotemax SM, its gel drop formulation for the treatment of postoperative inflammation and pain following ocular surgery, in the United States, according to a press release.

Lotemax SM (loteprednol etabonate ophthalmic gel 0.38%) delivers a submicron particle size that penetrates better to the aqueous humor as compared with Lotemax Gel 0.5%.

“Lotemax SM is the culmination of our clinical experience with the loteprednol etabonate compound for more than two decades,” Joe Gordon, U.S. president, Bausch + Lomb, said in the release. “We are extremely proud to make this new treatment option available, our most advanced loteprednol etabonate formulation to date, to help our customers address the needs of their patients undergoing ocular surgery who experience postoperative inflammation and pain.”

The new gel drop formulation was approved by the FDA on Feb. 22.